Urine iodine excretion in patients with papillary thyroid cancer evaluation of the relationship with the presence of BRAF mutation

The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis

“…The sample size of the included studies ranged from 132 to 2,041. 5 of these articles explored the level of UIC in PTC patients versus healthy controls ( 22 , 26 , 29 – 31 ), 7 of them examined UIC in PTC patients versus non-PTC patients(including patients with benign thyroid nodules, nodular goiter, and thyroid adenomas) ( 22 , 24 – 27 , 30 , 31 ), 3 of them studied the relationship between UIC and BRAF mutation in PTC patients ( 23 , 25 , 29 ), and 3 cases examined the relationship between UIC and LNM in patients with PTC ( 23 , 28 , 29 ). We divided urinary iodine into four categories according to the data in these articles.…”

“…We selected 3 articles ( 23 , 25 , 29 ) that compared the association between different levels of UIC and the occurrence of BRAF mutation in PTC patients and did not find significant differences in the levels of UIC between the BRAF mutation positive and negative groups ( Figure 4 ). This may suggest that excessive iodine intake (OR 0.95, 95%CI 0.51-1.78, P=0.88, n=546) ( Figure 4A ), above requirements (OR 1.02, 95%CI 0.50-2.07, P=0.96, n=546) ( Figure 4B ), moderate (OR 0.85, 95%CI 0.52-1.40, P=0.53, n=634) ( Figure 4C ) or deficiency (OR 1.32, 95%CI 0.66-2.66, P=0.43, n=634) ( Figure 4D ) do not affect the occurrence of the BRAF mutation in PTC patients.…”